Phase 2 vs Phase 3 — Immunology Deal Valuation Comparison

Phase 2 Median Upfront

$480M

Total: $2.5B

Phase 3 Median Upfront

$789M

Total: $3.1B

Stage Premium

22%

Phase 3 premium over Phase 2

Phase 2 Royalties

13.2%-22.1%

vs Phase 3: 17.7%-27.6%

Model Your Deal

Market Analysis

The Phase 2 to Phase 3 transition in immunology represents a significant value inflection point. Phase 3 deals carry a median total deal value of $3.1B compared to $2.5B at Phase 2, a 22% premium reflecting clinical de-risking. Upfront payments increase from $480M to $789M.

Deal structures shift as assets advance. Phase 2 deals allocate 19% to upfront and 81% to milestones, while Phase 3 deals shift to 26%/74%. Development milestones move from $405M to $227M, and royalty rates evolve from 13.2%-22.1% to 17.7%-27.6%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 2 to Phase 3 in immunology?

Phase 3 immunology deals command a 22% premium over Phase 2 in total deal value ($3.1B vs $2.5B). Upfronts increase from $480M to $789M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 2 and Phase 3 in immunology?

Phase 2 deals are more milestone-weighted (81% milestones), reflecting higher clinical risk. Phase 3 deals shift toward higher upfront allocations (26% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a immunology asset?

The optimal licensing window depends on strategic priorities. Phase 2 assets offer lower entry cost for licensees, while Phase 3 assets provide more certainty. The 22% premium from Phase 2 to Phase 3 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included